Interferon- β Therapy in Multiple Sclerosis

摘要: There have been considerable advances made recently in the treatment of multiple sclerosis (MS). In particular, interferon (IFN)β has demonstrated several independent, multicentre clinical trials to lower unequivocally biological activity this illness. The results these remarkably consistent, demonstrating a reduction both disease and cumulative disability, using combination magnetic resonance imaging outcome measures. Nevertheless, importance total weekly IFNβ dose management individual patients controversial. However, there is information available regarding effect on various biochemical markers that are affected by IFNβ, which derived from pre-clinical studies trials. On balance, convincing evidence provided support notion clinically relevant dose-response use treat with relapsing/remitting MS. many MS confounded potential effects possible frequency administration. As result, it apparent observed may be due, part, more frequent administration schedule rather than dose.